The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC).
Vanesa Gregorc
No relevant relationships to disclose
Nicoletta Zilembo
No relevant relationships to disclose
Francesco Grossi
No relevant relationships to disclose
Tommaso M De Pas
No relevant relationships to disclose
Gilda Rossoni
No relevant relationships to disclose
Filippo Pietrantonio
No relevant relationships to disclose
Erika Rijavec
No relevant relationships to disclose
Giovanni Citterio
No relevant relationships to disclose
Antonio Lambiase
Employment or Leadership Position - MolMed
Claudio Bordignon
No relevant relationships to disclose